Active surveillance for prostate cancer: a narrative review of clinical guidelines

Autor: Bruinsma, SM, Bangma, CH, Carroll, PR, Leapman, MS, Rannikko, A, Petrides, N, Weerakoon, M, Bokhorst, LP, Roobol, MJ, Ehdaie, B, Fahey, M, Filson, C, Frydenberg, M, Gnanapragasam, V, Kakehi, Y, Kattan, M, Klotz, L, Lophatananon, A, Malouf, D, Moore, C, Muir, K, Parker, C, Pickles, T, Sanda, M, Steyerberg, E, Trock, B, Valdagni, R, Kwast, TVD, Villers, A, Gillespie, TW, Zhang, L

In the past decade active surveillance (AS) of men with localized prostate cancer has become an increasingly popular management option, and a range of clinical guidelines have been published on this topic. Existing guidelines regarding AS for prostat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0bf08e464f37b2635eaa497e0081311
https://www.repository.cam.ac.uk/handle/1810/267038

Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.

Autor: Ajjawi I; Yale School of Medicine, New Haven, Connecticut., Loeb S; Department of Urology, New York University Langone Health, New York.; Manhattan Veterans Affairs Medical Center, New York, New York., Cooperberg MR; Department of Urology, University of California, San Francisco.; Department of Epidemiology and Biostatistics, University of California, San Francisco., Catalona WJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Gross CP; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.; Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut., Ma X; Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Leapman MS; Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut.; Department of Urology, Yale School of Medicine, New Haven, Connecticut.

Publikováno v: JAMA [JAMA] 2024 Nov 20. Date of Electronic Publication: 2024 Nov 20.

Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy.

Autor: Lokeshwar SD; Yale University, School of Medicine, Department of Urology, New Haven, CT., Choksi AU; Yale University, School of Medicine, Department of Urology, New Haven, CT., Smani S; Yale University, School of Medicine, Department of Urology, New Haven, CT., Kong V; Yale University, School of Medicine, Department of Urology, New Haven, CT., Sundaresan V; Yale University, School of Medicine, Department of Urology, New Haven, CT., Sutherland R; Yale University, School of Medicine, Department of Urology, New Haven, CT., Brito J; Yale University, School of Medicine, Department of Urology, New Haven, CT., Renzulli JF; Yale University, School of Medicine, Department of Urology, New Haven, CT., Sprenkle PC; Yale University, School of Medicine, Department of Urology, New Haven, CT., Leapman MS; Yale University, School of Medicine, Department of Urology, New Haven, CT. Electronic address: michael.leapman@yale.edu.

Publikováno v: Urologic oncology [Urol Oncol] 2024 Nov 08. Date of Electronic Publication: 2024 Nov 08.

Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.

Autor: Sundaresan VM; Department of Urology, Yale School of Medicine, New Haven, Connecticut., Wang R; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Long JB; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Sprenkle PC; Department of Urology, Yale School of Medicine, New Haven, Connecticut., Seibert TM; Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.; Department of Radiology, University of California, San Diego, La Jolla, California.; Department of Bioengineering, University of California, San Diego, La Jolla, California., Loeb S; Departments of Urology and Population Health, New York University Langone Health, New York, New York.; Manhattan Veterans Affairs Medical Center, New York, New York., Cooperberg MR; Department of Urology, University of California, San Francisco, San Francisco, California.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California., Catalona WJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Ma X; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Gross CP; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Leapman MS; Department of Urology, Yale School of Medicine, New Haven, Connecticut.; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.

Publikováno v: Urology practice [Urol Pract] 2024 Nov; Vol. 11 (6), pp. 965-973. Date of Electronic Publication: 2024 Jul 16.

Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients with Low-Risk Prostate Cancer in the Community Practice.

Autor: Gaylis FD; Division of Urology, Genesis Healthcare Partners, San Diego, California., Leapman MS; Department of Urology, Yale School of Medicine, New Haven, Connecticut., Ellis SD; Department of Population Health, Kansas University Medical Center, The University of Kansas., Hu S; Preveta Inc, California., Cooperberg MR; Department of Urology, University of California San Francisco, San Francisco, California.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Loeb S; Departments of Urology and Population Health, New York University Langone Health, New York, New York.; Manhattan Veterans Affairs Medical Center, New York, New York., Chen RC; Department of Radiation Oncology, Kansas University Medical Center, The University of Kansas., Cohen ES; Division of Urology, Genesis Healthcare Partners, San Diego, California., Dato PE; Division of Urology, Genesis Healthcare Partners, San Diego, California., Aynehchi S; Division of Urology, Genesis Healthcare Partners, San Diego, California., David R; Division of Urology, Genesis Healthcare Partners, San Diego, California., Topp R; College of Nursing, University of Kentucky, Lexington, Kentucky., Santomauro B; Division of Urology, Genesis Healthcare Partners, San Diego, California., Ginsburg K; Department of Urology, Wayne State University School of Medicine, Detroit. Michigan., Catalona WJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Publikováno v: Urology practice [Urol Pract] 2024 Oct 25, pp. 101097UPJ0000000000000745. Date of Electronic Publication: 2024 Oct 25.